{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:17:34Z","timestamp":1792466254915,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Delayed administration of polymyxin B hemoperfusion (PMX-HP) for septic shock could diminish its efficacy in real-world clinical settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>BEAT-SHOCK (BEst Available Treatment for septic SHOCK) registry is a prospective registry consisting of 309 adult patients with septic shock requiring high-dose norepinephrine (\u2265\u20090.2\u00a0\u03bcg\/kg\/min). This predetermined analysis included 82 patients treated with PMX-HP. They were grouped according to the median time from intensive care unit (ICU) admission to administration of PMX-HP: the early administration group (n\u2009=\u200940) and the late administration group (n\u2009=\u200942). The primary outcome was short-term hemodynamic status, including mean arterial pressure and vasoactive-inotropic score (VIS; calculated from doses of dopamine, dobutamine, norepinephrine, epinephrine, vasopressin, milrinone, and levosimendan) within 48\u00a0h after ICU admission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median time from ICU admission to administration of PMX-HP was 265\u00a0min (interquartile range [IQR]: 113\u2013480). The median ages were 70 (IQR: 59\u201381) and 72 (IQR: 64\u201380) years (<jats:italic>P<\/jats:italic>\u2009=\u20090.77), and 21\/40 (53%) and 25\/42 (60%) patients were male (<jats:italic>P<\/jats:italic>\u2009=\u20090.52) in the early and late administration groups, respectively. The dose of norepinephrine at ICU admission was 0.33 (IQR: 0.24\u20130.47) and 0.30 (IQR: 0.22\u20130.34) \u03bcg\/kg\/min in the early and late administration groups, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.17). Within 48\u00a0h after ICU admission, mean arterial pressure was significantly higher at 6\u00a0h and 8\u00a0h, and VIS was significantly lower at 8\u00a0h and thereafter in the early administration group. Within a 28-day period, there were 23 (IQR: 21\u201325) and 21 (IQR: 0\u201324) vasopressor\/inotrope-free days (<jats:italic>P<\/jats:italic>\u2009=\u20090.027), and 18 (IQR: 1\u201323) and 14 (IQR: 0\u201319) ICU-free days (<jats:italic>P<\/jats:italic>\u2009=\u20090.025) in the early and late administration groups, respectively. The cumulative mortality at 90\u00a0days was 15.3% in the early administration group and 31.3% in the late administration group (adjusted hazard ratio 0.38; 95% confidence interval 0.13\u20131.09).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In patients with septic shock, early administration of PMX-HP was associated with higher mean arterial pressure and lower VIS within 48\u00a0h after ICU admission. Additionally, it may be associated with an improved clinical course, represented by more ICU-free and vasopressor\/inotrope-free days.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic> UMIN Clinical Trial Registry on 1 November 2019 (registration no. UMIN000038302).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13054-025-05422-7","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T03:23:55Z","timestamp":1746761035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Time to administer polymyxin B hemoperfusion and hemodynamics in patients with septic shock requiring high-dose norepinephrine: a predetermined analysis of a prospective cohort study"],"prefix":"10.1186","volume":"29","author":[{"given":"Kyohei","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihito","family":"Kyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Hanajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"5422_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:775\u201387. https:\/\/doi.org\/10.1001\/jama.2016.0289.","journal-title":"JAMA"},{"key":"5422_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"key":"5422_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/ccm.0000000000003119","volume":"46","author":"MM Levy","year":"2018","unstructured":"Levy MM, Evans LE, Rhodes A. The surviving sepsis campaign bundle: 2018 update. Crit Care Med. 2018;46:997\u20131000. https:\/\/doi.org\/10.1097\/ccm.0000000000003119.","journal-title":"Crit Care Med"},{"key":"5422_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00134-013-3131-5","volume":"40","author":"DT Noritomi","year":"2014","unstructured":"Noritomi DT, Ranzani OT, Monteiro MB, Ferreira EM, Santos SR, Leibel F, et al. Implementation of a multifaceted sepsis education program in an emerging country setting: clinical outcomes and cost-effectiveness in a long-term follow-up study. Intensive Care Med. 2014;40:182\u201391. https:\/\/doi.org\/10.1007\/s00134-013-3131-5.","journal-title":"Intensive Care Med"},{"key":"5422_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13054-016-1243-3","volume":"20","author":"AP Houwink","year":"2016","unstructured":"Houwink AP, Rijkenberg S, Bosman RJ, van der Voort PH. The association between lactate, mean arterial pressure, central venous oxygen saturation and peripheral temperature and mortality in severe sepsis: a retrospective cohort analysis. Crit Care. 2016;20:56. https:\/\/doi.org\/10.1186\/s13054-016-1243-3.","journal-title":"Crit Care"},{"key":"5422_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/ccm.0000000000004476","volume":"48","author":"RJ Roberts","year":"2020","unstructured":"Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen JT, Phillips KM, et al. Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med. 2020;48:1445\u201353. https:\/\/doi.org\/10.1097\/ccm.0000000000004476.","journal-title":"Crit Care Med"},{"key":"5422_CR7","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445\u201352. https:\/\/doi.org\/10.1001\/jama.2009.856.","journal-title":"JAMA"},{"key":"5422_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320:1455\u201363. https:\/\/doi.org\/10.1001\/jama.2018.14618.","journal-title":"JAMA"},{"key":"5422_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10047-016-0922-9","volume":"20","author":"S Chihara","year":"2017","unstructured":"Chihara S, Masuda Y, Tatsumi H, Nakano K, Shimada T, Murohashi T, et al. Early induction of direct hemoperfusion with a polymyxin-B immobilized column is associated with amelioration of hemodynamic derangement and mortality in patients with septic shock. J Artif Organs. 2017;20:71\u20135. https:\/\/doi.org\/10.1007\/s10047-016-0922-9.","journal-title":"J Artif Organs"},{"key":"5422_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041009","author":"JH Lee","year":"2024","unstructured":"Lee JH, Han WH, Im HJ, Kim JH. Effects of early initiation of polymyxin B hemoperfusion therapy in patients with cancer with refractory septic shock. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13041009.","journal-title":"J Clin Med"},{"key":"5422_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000336341","volume":"33","author":"N Takeyama","year":"2012","unstructured":"Takeyama N, Noguchi H, Hirakawa A, Kano H, Morino K, Obata T, et al. Time to initiation of treatment with polymyxin B cartridge hemoperfusion in septic shock patients. Blood Purif. 2012;33:252\u20136. https:\/\/doi.org\/10.1159\/000336341.","journal-title":"Blood Purif"},{"key":"5422_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.446","volume":"7","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Tabata T, Fujino K, Tsujita Y, Eguchi Y. Impact of timing of polymyxin B-immobilized fiber column direct hemoperfusion on outcome in patients with septic shock: a single-center observational study. Acute Med Surg. 2020;7: e446. https:\/\/doi.org\/10.1002\/ams2.446.","journal-title":"Acute Med Surg"},{"key":"5422_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13613-016-0178-9","volume":"6","author":"SL Cutuli","year":"2016","unstructured":"Cutuli SL, Artigas A, Fumagalli R, Monti G, Ranieri VM, Ronco C, et al. Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry. Ann Intensive Care. 2016;6:77. https:\/\/doi.org\/10.1186\/s13613-016-0178-9.","journal-title":"Ann Intensive Care"},{"key":"5422_CR14","unstructured":"Japan MoHLW. Ethical Guidelines for Medical and Biological Research Involving Human Subjects. (https:\/\/www.mhlw.go.jp\/content\/001077424.pdf). (Accessed 13 Aug 2024)."},{"key":"5422_CR15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000491744","volume":"46","author":"Y Kawazoe","year":"2018","unstructured":"Kawazoe Y, Sato T, Miyagawa N, Yokokawa Y, Kushimoto S, Miyamoto K, et al. mortality effects of prolonged hemoperfusion therapy using a polymyxin B-immobilized fiber column for patients with septic shock: a sub-analysis of the desire trial. Blood Purif. 2018;46:309\u201314. https:\/\/doi.org\/10.1159\/000491744.","journal-title":"Blood Purif"},{"key":"5422_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40560-017-0214-3","volume":"5","author":"K Miyamoto","year":"2017","unstructured":"Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J Intensive Care. 2017;5:19. https:\/\/doi.org\/10.1186\/s40560-017-0214-3.","journal-title":"J Intensive Care"},{"key":"5422_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bja.2018.12.019","volume":"122","author":"T Koponen","year":"2019","unstructured":"Koponen T, Karttunen J, Musialowicz T, Pietil\u00e4inen L, Uusaro A, Lahtinen P. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth. 2019;122:428\u201336. https:\/\/doi.org\/10.1016\/j.bja.2018.12.019.","journal-title":"Br J Anaesth"},{"key":"5422_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40560-019-0383-3","volume":"7","author":"T Abe","year":"2019","unstructured":"Abe T, Ogura H, Kushimoto S, Shiraishi A, Sugiyama T, Deshpande GA, et al. Variations in infection sites and mortality rates among patients in intensive care units with severe sepsis and septic shock in Japan. J Intensive Care. 2019;7:28. https:\/\/doi.org\/10.1186\/s40560-019-0383-3.","journal-title":"J Intensive Care"},{"key":"5422_CR19","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"5422_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"5422_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433.","journal-title":"Am J Epidemiol"},{"key":"5422_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2022.23257","volume":"329","author":"AM Higgins","year":"2023","unstructured":"Higgins AM, Berry LR, Lorenzi E, Murthy S, McQuilten Z, Mouncey PR, et al. Long-term (180-Day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39\u201351. https:\/\/doi.org\/10.1001\/jama.2022.23257.","journal-title":"JAMA"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05422-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T03:23:58Z","timestamp":1746761038000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05422-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5422"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05422-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics committee of Tohoku University Hospital (Approval Number 2019-1-402) and the ethics committees of all other participating hospitals approved this study with an opt-out policy in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Written informed consent was obtained from patients or their proxies to collect data about functional outcomes at 90\u00a0days by distributing questionnaires. This study was conducted in compliance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The ethics committee of Tohoku University Hospital (approval number 2019-1-402) and the ethics committees of all other participating hospitals approved this study with an opt-out policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Miyamoto reports lecturer's fees from Asahi Kasei Pharma, Japan Blood Products Organization, and Chugai Pharmaceutical. Dr. Kawazoe reports lecturer\u2019s fees from Toray Industries Inc. and Asahi Kasei Pharma. Dr. Kyo reports lecturer's fee from TXP Medical. Dr. Masaki Takahashi reports lecture's fees from Japan Blood Products Organization and Eisai Co., Ltd.. Dr. Gaku Takahashi reports lecturer\u2019s fees from Toray Industries Inc. and Asahi Kasei Pharma. and JB Pharma. Dr. Hanajima reports lecturer's fee from Toray Industries Inc.. Dr Morimoto reports lecturer's fees from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Pfizer, Tsumura and UCB; manuscript fee from Pfizer; advisory board for GlaxoSmithKline, Novartis and Teijin.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}